← Leaderboards
Yingda Linda Xie
Rutgers Biomedical And Health Sciences
$3,587,896
Attributed
$5,430,195
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,430,195 · 7
By mechanism
R01$3,850,659 · 3
R21$1,281,855 · 3
K22$297,681 · 1
Top collaborators
- Cameron Amadeus Myhrvold4 shared
- Padmapriya Banada2 shared
- Abraham Pinter2 shared
- Padmini Salgame2 shared
- David Alland1 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Stephan K Schwander$5,685,114
- David Alland$97,558,393
- Reynold Alexander Panettieri$65,091,349
Others in their field
Other Emerging Leaders on “Mycobacterium Tuberculosis”
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Jay Evans · University Of Montana$12,765,004
- Sujatha Rashid · American Type Culture Collection$10,735,388
- Anna Upton · Global Alliance For Tb Drug Development$10,496,979
Research focus
Mycobacterium TuberculosisDetectionTransmission ProcessSputumTuberculosisMorbidity - Disease RateSymptomsPerformanceDiagnosisDiagnosticMortalityEvaluationPhenotypeTechnologyResourcesValidationGene Expression ProfileBiological MarkersCohortParentsInfectionCommunicable DiseasesCase FindingFuture
Grant awards (14)
Transmission Links and Clinical Spectrum of Exhaled Mycobacterium Tuberculosis$1,032,233
R01 · FY2025 · AI · contact PI
Development of a highly-multiplexed CRISPR-based TB drug susceptibility test$702,499
R01 · FY2025 · AI · contact PI
Imaging signatures of early tuberculosis$642,787
R01 · FY2025 · AI · contact PI
Development of a highly-multiplexed CRISPR-based TB drug susceptibility test$791,030
R01 · FY2024 · AI · contact PI
Imaging signatures of early tuberculosis$682,110
R01 · FY2024 · AI · contact PI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$196,250
R21 · FY2023 · AI · contact PI
Development of a rapid multiplex CRISPR-based testing pathway for tuberculosis and COVID-19$193,004
R21 · FY2023 · AI · contact PI
[R21] Integrated computer-aided, point-of-care ultrasound for tuberculosis screening$189,664
R21 · FY2023 · AI · contact PI
Development of a rapid multiplex CRISPR-based testing pathway for tuberculosis and COVID-19$244,866
R21 · FY2022 · AI · contact PI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$235,007
R21 · FY2022 · AI · contact PI
[R21] Integrated computer-aided, point-of-care ultrasound for tuberculosis screening$223,064
R21 · FY2022 · AI · contact PI
Exploring the Early Tuberculosis Spectrum Through Highly-Sensitive Mtb DNA Detection$27,681
K22 · FY2021 · AI · contact PI
Exploring an Incipient Tuberculosis Spectrum Through Highly-Sensitive MTB DNA Detection$108,000
K22 · FY2020 · AI · contact PI
Exploring an Incipient Tuberculosis Spectrum Through Highly-Sensitive MTB DNA Detection$162,000
K22 · FY2019 · AI · contact PI